Gabapentin Market is witnessing dynamic changes driven by regulatory approvals, expanding generic competition, and increasing off-label utilization across multiple therapeutic areas. In a key regulatory development, Zydus Lifesciences Limited received final approval from the U.S. Food and Drug Administration (USFDA) on January 25, 2024, to manufacture and market once-daily Gabapentin tablets in 300 mg and 600 mg strengths. Notably, Zydus became the first company to secure approval for the generic version of these extended-release tablets, referencing the branded drug Gralise. The product, manufactured at the company’s Moraiya facility in Ahmedabad, was launched in the United States shortly after approval. According to IQVIA data, the reference market recorded annual sales of approximately USD 85 million as of November 2023, indicating a stable demand base for this formulation.
Further strengthening the competitive landscape, Strides Pharma Science Limited also secured USFDA approval in March 2024 for gabapentin tablets USP in higher strengths of 600 mg and 800 mg. These approvals reflect growing participation by Indian pharmaceutical companies in the U.S. generics market and highlight the importance of cost-effective alternatives in expanding patient access to essential neurological therapies. Gabapentin is primarily indicated for the management of postherpetic neuralgia, a type of nerve pain that occurs following shingles, but its clinical use has broadened significantly over time.
Beyond regulatory developments, the gabapentin market is also being shaped by its increasing off-label use. Originally approved as an anticonvulsant and later for neuropathic pain, gabapentin is now widely prescribed for conditions such as anxiety, insomnia, migraine, fibromyalgia, and postoperative pain. Its adoption accelerated after public health authorities recommended it as a safer alternative to opioid analgesics, contributing to its widespread use. By 2024, gabapentin had become one of the most prescribed drugs in the United States, with approximately 15.5 million prescriptions annually.
However, recent studies have raised concerns regarding the drug’s misuse and unregulated use, particularly in patients undergoing treatment for substance use disorder (SUD). Research published in Drug and Alcohol Dependence in January 2026 found that gabapentin prescribing in addiction treatment settings nearly doubled over the past decade. Additionally, a notable proportion of patients tested positive for gabapentin without having a prescription, suggesting potential misuse. The drug is sometimes used to manage withdrawal symptoms or enhance the effects of substances such as opioids, raising safety and regulatory concerns.
Despite these challenges, there are signs of improvement. The same research indicates that non-prescribed use of gabapentin has declined in recent years, suggesting increased awareness and monitoring. Nevertheless, the findings highlight the need for stronger clinical guidelines and evidence-based use, particularly in addiction treatment settings where its benefits remain uncertain.
Overall, the gabapentin market is characterized by strong generic growth, expanding therapeutic applications, and evolving regulatory oversight. While approvals from companies like Zydus Lifesciences Limited and Strides Pharma Science Limited are expected to enhance accessibility and affordability, concerns regarding misuse and off-label prescribing may influence future regulatory policies and prescribing behavior. As a result, the market is likely to continue evolving, balancing opportunities for growth with the need for responsible and evidence-based use.
